Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalMarket CapitalizationReturn on AssetsReturn on Capital EmployedReturn on Equity

Spyre Therapeutics (SYRE) EBT Margin: 2015-2023

Historic EBT Margin for Spyre Therapeutics (SYRE) over the last 5 years, with Jun 2023 value amounting to -31,551.45%.

  • Spyre Therapeutics' EBT Margin fell 2798121.00% to -31,551.45% in Q2 2023 from the same period last year, while for Jun 2023 it was -22,211.64%, marking a year-over-year decrease of 2171562.00%. This contributed to the annual value of -38,241.08% for FY2023, which is 3463649.00% down from last year.
  • As of Q2 2023, Spyre Therapeutics' EBT Margin stood at -31,551.45%, which was down 238.45% from -9,322.22% recorded in Q1 2023.
  • In the past 5 years, Spyre Therapeutics' EBT Margin registered a high of -151.82% during Q2 2021, and its lowest value of -31,551.45% during Q2 2023.
  • In the last 3 years, Spyre Therapeutics' EBT Margin had a median value of -3,570.24% in 2022 and averaged -7,655.52%.
  • Data for Spyre Therapeutics' EBT Margin shows a maximum YoY tumbled of 2,798,121bps (in 2023) over the last 5 years.
  • Over the past 3 years, Spyre Therapeutics' EBT Margin (Quarterly) stood at -560.46% in 2021, then plummeted by 1,062,050bps to -11,180.95% in 2022, then plummeted by 2,798,121bps to -31,551.45% in 2023.
  • Its EBT Margin stands at -31,551.45% for Q2 2023, versus -9,322.22% for Q1 2023 and -11,180.95% for Q4 2022.